Superior Planning, LLC’s Kymera Therapeutics KYMR Stock Holding History

Superior Planning, LLC’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10.2K	Buy	+91	New	+$10.4K	﹤0.01%	921

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Superior Planning, LLC's KYMR Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Kymera Therapeutics (KYMR) in Q3 2026: 91 shares worth $10.2K. The stake represents ﹤0.01% of the portfolio and ranks #921 among its holdings.

173 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

Superior Planning, LLC held 91 shares of Kymera Therapeutics worth $10.2K as of Q3 2026.
Kymera Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Kymera Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #921 holding.
173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.